We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

14 hedge funds and large institutions have $2.55M invested in Grace Therapeutics in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

12% more capital invested

Capital invested by funds: $2.29M → $2.55M (+$267K)

8% more funds holding

Funds holding: 13 → 14 (+1)

0.01% less ownership

Funds ownership: 0.07% → 0.07% (-0.01%)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
+$63.2K
2
UBS Group
UBS Group
Switzerland
+$27.3K
3
Deutsche Bank
Deutsche Bank
Germany
+$25.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$25.2K
5
PVI
Pura Vida Investments
New York
+$20.4K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$229K
2
Citadel Advisors
Citadel Advisors
Florida
-$50K
3
Bank of America
Bank of America
North Carolina
-$31K
4
KJHP
K.J. Harrison & Partners
Ontario, Canada
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$1.81M – – –
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$253K +$691 +14 +0.3%
PVI
3
Pura Vida Investments
New York
$212K +$20.4K +413 +11%
CH
4
CVI Holdings
Delaware
$63K +$63.2K +1,281 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$49K – – –
Morgan Stanley
6
Morgan Stanley
New York
$39K – – –
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Quebec, Canada
$36.9K – – –
UBS Group
8
UBS Group
Switzerland
$27K +$27.3K +553 New
Renaissance Technologies
9
Renaissance Technologies
New York
$25K +$25.2K +510 New
Deutsche Bank
10
Deutsche Bank
Germany
$24K +$25.2K +510 New
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$9K +$4.54K +92 +108%
TC
12
Truvestments Capital
Florida
$1K +$1.23K +25 New
RE
13
RBC Europe
United Kingdom
$31 – – –
SM
14
Sabby Management
Florida
– -$229K -5,729 Closed
Citadel Advisors
15
Citadel Advisors
Florida
– -$50K -1,255 Closed
Bank of America
16
Bank of America
North Carolina
– -$31K -787 Closed
KJHP
17
K.J. Harrison & Partners
Ontario, Canada
– -$28K -708 Closed

GRCE Hedge Fund Activity: Q1 2019 in Review

14 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2019, worth a combined $2.55M — up 12% from $2.29M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GRCE positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.

The largest buyer was CVI Holdings, opening a new position worth an estimated $63.2K. The largest seller was Sabby Management, exiting entirely with an estimated $229K sold.

  • 14 institutional investors held Grace Therapeutics (GRCE) as of Q1 2019, up from 13 in Q4 2018.
  • Funds reported $2.55M of Grace Therapeutics stock for Q1 2019, up 12% quarter-over-quarter.
  • 5 funds opened new Grace Therapeutics positions in Q1 2019 and 4 closed out, a net change of +1 holder.
  • The largest Grace Therapeutics buyer in Q1 2019 was CVI Holdings, an estimated $63.2K added.
  • The largest Grace Therapeutics seller in Q1 2019 was Sabby Management, an estimated $229K sold.

Based on aggregated 13F filings for Q1 2019.